GlassScriptPhysician profile
Wanda Kay Roark
NPI 1134332117
$5,206.47
in general payments reported to CMS, 2019-2025
23 companies · $722 in 2025
The $722 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $998 · 2022: $1,197 · 2023: $1,132 · 2024: $1,158 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.60 | 2021-2025 | |
| Amgen INC. | $564.80 | 2021-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $505.62 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $495.47 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $432.06 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $297.42 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $241.53 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $236.58 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.56 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $160.60 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $122.54 | 2021-2025 | Capvaxive, Vaxneuvance, Vaxelis |
| Dexcom, INC. | $110.67 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $109.29 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.33 | 2021-2024 | Jardiance |
| Mylan Specialty L.P. | $80.12 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $77.34 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.27 | 2021-2023 | Trintellix |
| Lilly USA, LLC | $62.05 | 2022-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $35.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.70 | 2022 | |
| Amarin Pharma, INC. | $29.92 | 2021-2022 | |
| Axsome Therapeutics, INC. | $17.09 | 2025 | Auvelity |
| Biogen, INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Roark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.